Navigation Links
NovaBay Pharmaceuticals Announces New Preclinical Data to be Presented at the American Academy of Dermatology (AAD) 67th Annual Meeting
Date:3/4/2009

elieves that NVC-422 may deliver the same or better efficacy as currently used antibiotics without giving rise to resistant bacteria. In past in-vitro studies, NVC-422 has shown a broad therapeutic index with broad spectrum activity against bacteria of all types, including multidrug resistant species, shedding viruses including adenoviruses and herpes viruses, yeasts and fungi. In addition, NVC-422 has previously shown, in-vivo, to be safe at expected therapeutic doses in the nose, bladder, wounds and eye. NVC-422 is protected by U.S. Patent #7,462,361 until 2026. In addition to Alcon's development in the eye, NovaBay has taken NVC-422 into Phase II human trials for infections in the nose and bladder and expects to begin a Phase II trial for the treatment of skin infections, including those caused by MRSA (Methicillin resistant Staphylococcus aureus), in 2009.

About NovaBay Pharmaceuticals, Inc.

NovaBay Pharmaceuticals is a clinical stage biopharmaceutical company developing first-in-class, novel, synthetic anti-infective product candidates that are bioequivalent to the active antimicrobial molecules generated within white blood cells to treat and prevent a wide range of infections without developing resistance. NovaBay has entered into a licensing and research collaboration agreement with Alcon, Inc. for use of the Aganocide compounds in the eye, ear and sinus, and in contact lens solutions. NovaBay(R) and Aganocide(R) are trademarks of NovaBay Pharmaceuticals, Inc. For more information on NovaBay, visit www. novabaypharma.com.

Cautionary Information Regarding Forward-Looking Statements

The statements in this press release regarding the potential efficacy of NVC-422 and NovaBay's expectation to begin a Phase II trial for the treatment of skin infections in 2009 are forward-looking statements. These statements are subject to risks and uncertainties that could cau
'/>"/>

SOURCE NovaBay Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. NovaBay Pharmaceuticals Closes Initial Public Offering of Common Stock
2. NovaBay announces third quarter 2007 financial results
3. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
4. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
5. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
6. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
7. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
8. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
9. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
10. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
11. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/22/2014)... percent of all lung cancers are small cell ... develop resistance to chemotherapy. However, researchers at Virginia ... insights into the mechanisms leading to this resistance ... Chemotherapies work primarily by mediating B-cell lymphoma 2 ... cell death. Depending on their function, this family ...
(Date:4/22/2014)... 2014Hemoglobin A1c is the standard measurement for assessing glycemic ... of A1c are typically measured every few months in ... model that accurately estimates A1c using self-monitored blood glucose ... Therapeutics ( DTT ), a peer-reviewed journal from ... free on the DTT website at ...
(Date:4/22/2014)... PHILADELPHIA (April 22, 2014) That person we all seem ... take action? Turns out he or she isn,t unable to ... A study of nearly ... about why neurotic people may avoid making decisions and moving ... if action is positive, favorable, good, they just don,t like ...
(Date:4/22/2014)... -- In parallel with modern man ( Homo sapiens ), ... we lived side by side, such as Neanderthals and the ... sapiens survived. What was it in our genetic makeup ... little is known about our unique genetic makeup as distinguished ... fact that we are the only species among them ,to ...
(Date:4/22/2014)... Disease (IBD), a group of chronic inflammatory disorders of ... affects over 1.4 million people in the U.S., and ... there is no cure. , Now, Cincinnati Cancer ... Susan Waltz, PhD, and scientists in her lab have ... genetic study to document the important function for the ...
Breaking Medicine News(10 mins):Health News:Scientists pinpoint protein that could improve small cell lung cancer therapies 2Health News:Neurotics don't just avoid action: They dislike it 2Health News:What gave us the advantage over extinct types of humans? 2Health News:Two genes linked to inflammatory bowel disease 2
... and predicting the tumours that will metastasize in lymph nodes ... 3rd International Conference on innovative approaches in Head and Neck ... Radboud University Nijmegen Medical Centre, the Netherlands, reported results of ... The study was jointly led by scientists from Nijmegen and ...
... Michigan State University has secured a $7.9 million ... Mozambique through increasing the African nation,s agricultural productivity, ... four-year grant, funded by the U.S. Agency for ... University of Florida. The initiative employs trilateral cooperation, ...
... of the factors reported by those who say they are unhappy ... its kind, published in the launch issue of the new online ... challenge the perception that these patients can no longer enjoy quality ... the authors. The research team quizzed 168 members of the ...
... four new grants to help improve awareness, prevention and ... in China and India. The grants total nearly $1 ... hepatitis-related health disparities in Asia to $8 million USD ... announced at the Asian Pacific Association for the Study ...
... 24 (HealthDay News) -- An analysis of proteins in spinal ... with chronic fatigue syndrome, a new study reports. It ... involve the central nervous system and that protein abnormalities in ... conditions, said the research team, which was led by Dr. ...
... suffer from delirium each year, however the condition goes ... if diagnosed, there is no effective way to treat ... professionals. Researchers, clinicians, and administrators from across ... - 7 for "Advancing Delirium Care through Research," the ...
Cached Medicine News:Health News:Gene expression to distinguish metastasizing from non-metastasizing head and neck cancers 2Health News:$7.9 million grant to improve food security, nutrition in Mozambique 2Health News:Most 'locked-in syndrome' patients say they are happy 2Health News:Bristol-Myers Squibb Foundation awards nearly $1M to HBV, HCV awareness, prevention and care 2Health News:Bristol-Myers Squibb Foundation awards nearly $1M to HBV, HCV awareness, prevention and care 3Health News:Spinal Fluid May Hold Clues to Lyme Disease, Chronic Fatigue Syndrome 2Health News:Advancing delirium care through research 2
(Date:1/15/2014)... 2014 Reportlinker.com announces that a new ... catalogue: PharmaPoint: Atopic ... Analysis to 2022 http://www.reportlinker.com/p01957657/PharmaPoint-Atopic-Dermatitis---India-Drug-Forecast-and-Market-Analysis-to-2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology ... India Drug Forecast and Market Analysis to ...
(Date:1/15/2014)... , Jan. 15, 2014  Zafgen, Inc., a leading ... of severely obese patients, today announced initial results ... selective inhibitor of methionine aminopeptidase 2 (MetAP2), in ... of genetic obesity.  These results showed improvements in ...
(Date:1/14/2014)... , Jan. 14, 2014 InformEx, North America,s ... of high-value chemistry, will hold the 30 th edition ... Convention Center from January 21-24. (Logo: ... from top pharmaceutical, fine chemical and specialty chemical companies will ...
Breaking Medicine Technology:PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2
Inquire...
Rapid Urease test for the presumptive identification of H. pylori in gastric mucosal biopsies...
... The QuickVue H.pylori gII test is a ... qualitative detection of IgG antibodies specific to ... whole blood. It utilizes a convenient, non-invasive, ... aid physicians in the diagnosis of H.pylori ...
... a visually read, qualitative immunochromatographic method for ... a bacterium that grows in the stomach ... and some gastric cancers. FlexSure HP, available ... serum samples, provides the physician with the ...
Medicine Products: